Press Releases

• May 20, 2021 Rezolute Expands Leadership Team with the Appointment of Davelyn Hood, MD as Director, Scientific and Patient Affairs
• May 18, 2021 Rezolute Appoints Leading Ophthalmology Expert, Quan Dong Nguyen, MD, MSc, FAAO, FARVO, to Scientific Advisory Board
• May 17, 2021 Rezolute Reports Third Quarter Fiscal 2021 Financial Results and Highlights Recent Company Progress
• May 17, 2021 Rezolute to Present at the Oppenheimer Rare and Orphan Disease Summit
• May 4, 2021 Rezolute Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema
• Apr 19, 2021 Rezolute Announces $30 Million Debt Financing Agreement with SLR Capital Partners
• Mar 22, 2021 Rezolute Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021
• Mar 8, 2021 Rezolute Strengthens Board of Directors with Key Appointments of Leading Rare Disease Experts
• Mar 2, 2021 Rezolute to Participate in Upcoming Investor Conferences in March
• Feb 10, 2021 Rezolute Reports Second Quarter Fiscal 2021 Financial Results